Adel, Tameem
Cohen, Taco
Caan, Matthan
Welling, Max
Funding for this research was provided by:
NWO IPPSI-KIEM (628.005.012)
SURF Foundation
Nuts-OHRA Foundation (1003-026)
Netherlands Organisation for Health Research and Development
AIDS Fonds (300020007)
AIDS Fonds (2009063)
Gilead Sciences
ViiV Healthcare
Janssen Pharmaceutica N.V.
Bristol-Myers Squibb
Boehringer Ingelheim
Merck&Co
Alzheimer's Disease Neuroimaging Initiative
National Institutes of Health (U01 AG024904)
DOD
ADNI
Department of Defense (W81XWH-12-2-0012)
National Institute on Aging
National Institute of Biomedical Imaging and Bioengineering
AbbVie
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Araclon Biotech
BioClinica, Inc.
Biogen
Bristol-Myers Squibb Company
CereSpir, Inc.
Eisai Inc.
Elan Pharmaceuticals, Inc.
Eli Lilly and Company
EuroImmun
F. Hoffmann-La Roche Ltd
Genentech, Inc.
Fujirebio
GE Healthcare
IXICO Ltd.
Janssen Alzheimer Immunotherapy Research & Development, LLC.
Johnson & Johnson Pharmaceutical Research & Development LLC.
Lumosity
Lundbeck
Merck & Co., Inc.
Meso Scale Diagnostics, LLC.
NeuroRx Research
Neurotrack Technologies
Novartis Pharmaceuticals Corporation
Pfizer Inc.
Piramal Imaging
Servier
Takeda Pharmaceutical Company
Transition Therapeutics
Canadian Institutes of Health Research
Foundation for the National Institutes of Health
This article is maintained by: Elsevier
Article Title: 3D scattering transforms for disease classification in neuroimaging
Journal Title: NeuroImage: Clinical
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.nicl.2017.02.004
Content Type: article
Copyright: © 2017 The Authors. Published by Elsevier Inc.